On September 11, local time, AstraZeneca announced that the SERENA-4 phase III trial for first-line treatment of ER-positive and HER2-negative advanced breast cancer with the oral selective estrogen receptor degrading agent etcamah combined with pabosinib did not reach the main end. Although there was a numerical improvement in the patients' progression-free survival, it was not statistically significant. AstraZeneca said the safety of the combination was consistent with known conditions, and no new safety issues were found.

On September 11, local time, AstraZeneca announced that the SERENA-4 phase III trial for first-line treatment of ER-positive and HER2-negative advanced breast cancer with the oral selective estrogen receptor degrading agent etcamah combined with pabosinib did not reach the main end. Although there was a numerical improvement in the patients' progression-free survival, it was not statistically significant. AstraZeneca said the safety of the combination was consistent with known conditions, and no new safety issues were found.